Cargando…

Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia

Because of an elevated serum phosphate level, patients who suffer from chronic kidney failure frequently tend to have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event. Phosphate binders are able to reduce these negative effects. Currently, there are pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Plagemann, Thomas, Prenzler, Anne, Mittendorf, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395041/
https://www.ncbi.nlm.nih.gov/pubmed/22828213
http://dx.doi.org/10.1186/2191-1991-1-1
_version_ 1782237927162511360
author Plagemann, Thomas
Prenzler, Anne
Mittendorf, Thomas
author_facet Plagemann, Thomas
Prenzler, Anne
Mittendorf, Thomas
author_sort Plagemann, Thomas
collection PubMed
description Because of an elevated serum phosphate level, patients who suffer from chronic kidney failure frequently tend to have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event. Phosphate binders are able to reduce these negative effects. Currently, there are primarily two groups of phosphate binders (calcium-containing and calcium-free phosphate binders) which are considered to be almost equally effective in terms of binding of free phosphate. There are, however, a few disadvantages of the two groups. While the calcium-containing binders are associated with an increased risk of hypercalcemia, which is dose dependent, calcium-free binders have been criticized as being too expensive. As the expenditure for patients suffering from chronic kidney failure increases from year to year, as a result of increasing prevalence, there is a growing need for an alternative to existing phosphate binders. The study presented here therefore summarizes available information for the novel combination preparation OsvaRen(® )(calcium acetate/magnesium carbonate) as an alternative therapy to the calcium-free phosphate binder Renagel(® )(sevelamer-hydrochloride) and to calcium-containing preparations. The results of this systematic review showed that OsvaRen(® )is at least equally effective in the regulation of serum phosphate level as Renagel(®). In particular, OsvaRen(® )shows no clinically relevant difference in terms of the control of the serum calcium levels compared to Renagel(® )and thereby does not increase the risk of a hypercalcaemia, in contrast to pure calcium-based phosphate binders. On the other hand, Renagel(® )therapy is much more frequently associated with gastrointestinal side-effects, a tendency to result in higher tablet burden for patients and high medication costs. The CALMAG study showed that OsvaRen(® )was at least as effective and safe in terms of controlling serum phosphate and serum calcium levels as Renagel(® )while, at the same time, resulting in about 80% lower costs. In addition, OsvaRen(® )offers a lower risk of hypercalcaemia and associated subsequent costs and is thereby also superior to pure calcium-containing phosphate binders. Because of the effectiveness and tolerability of calcium acetate/magnesium carbonate, OsvaRen(® )offers a clinically suitable and, at the same time, cost-effective therapeutic option in the therapy of hyperphosphataemia.
format Online
Article
Text
id pubmed-3395041
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Springer
record_format MEDLINE/PubMed
spelling pubmed-33950412012-07-16 Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia Plagemann, Thomas Prenzler, Anne Mittendorf, Thomas Health Econ Rev Review Because of an elevated serum phosphate level, patients who suffer from chronic kidney failure frequently tend to have cardiovascular calcification and are therefore exposed to a higher probability of a fatal event. Phosphate binders are able to reduce these negative effects. Currently, there are primarily two groups of phosphate binders (calcium-containing and calcium-free phosphate binders) which are considered to be almost equally effective in terms of binding of free phosphate. There are, however, a few disadvantages of the two groups. While the calcium-containing binders are associated with an increased risk of hypercalcemia, which is dose dependent, calcium-free binders have been criticized as being too expensive. As the expenditure for patients suffering from chronic kidney failure increases from year to year, as a result of increasing prevalence, there is a growing need for an alternative to existing phosphate binders. The study presented here therefore summarizes available information for the novel combination preparation OsvaRen(® )(calcium acetate/magnesium carbonate) as an alternative therapy to the calcium-free phosphate binder Renagel(® )(sevelamer-hydrochloride) and to calcium-containing preparations. The results of this systematic review showed that OsvaRen(® )is at least equally effective in the regulation of serum phosphate level as Renagel(®). In particular, OsvaRen(® )shows no clinically relevant difference in terms of the control of the serum calcium levels compared to Renagel(® )and thereby does not increase the risk of a hypercalcaemia, in contrast to pure calcium-based phosphate binders. On the other hand, Renagel(® )therapy is much more frequently associated with gastrointestinal side-effects, a tendency to result in higher tablet burden for patients and high medication costs. The CALMAG study showed that OsvaRen(® )was at least as effective and safe in terms of controlling serum phosphate and serum calcium levels as Renagel(® )while, at the same time, resulting in about 80% lower costs. In addition, OsvaRen(® )offers a lower risk of hypercalcaemia and associated subsequent costs and is thereby also superior to pure calcium-containing phosphate binders. Because of the effectiveness and tolerability of calcium acetate/magnesium carbonate, OsvaRen(® )offers a clinically suitable and, at the same time, cost-effective therapeutic option in the therapy of hyperphosphataemia. Springer 2011-07-20 /pmc/articles/PMC3395041/ /pubmed/22828213 http://dx.doi.org/10.1186/2191-1991-1-1 Text en Copyright ©2011 Prenzler et al; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Plagemann, Thomas
Prenzler, Anne
Mittendorf, Thomas
Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
title Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
title_full Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
title_fullStr Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
title_full_unstemmed Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
title_short Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
title_sort considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395041/
https://www.ncbi.nlm.nih.gov/pubmed/22828213
http://dx.doi.org/10.1186/2191-1991-1-1
work_keys_str_mv AT plagemannthomas considerationsabouttheeffectivenessandcosteffectivenessoftherapiesinthetreatmentofhyperphosphataemia
AT prenzleranne considerationsabouttheeffectivenessandcosteffectivenessoftherapiesinthetreatmentofhyperphosphataemia
AT mittendorfthomas considerationsabouttheeffectivenessandcosteffectivenessoftherapiesinthetreatmentofhyperphosphataemia